1,632 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Worth Asset Management LLC

Key Points

• Worth Asset Management purchased 1,632 Thermo Fisher Scientific shares worth approximately $1.1 million in the third quarter. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly results above expectations, with EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. Analysts project approximately $25.13 in fiscal 2026 EPS.
• TMO shares recently traded at $665.64, near their 52-week high, while the company announced a quarterly dividend of $0.47 per share. The stock has a “Moderate Buy” consensus rating, although some insiders have recently sold shares and Wells Fargo downgraded it to “underweight.”

Worth Asset Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,632 shares of the medical research company's stock, valued at approximately $1,102,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Tsfg LLC lifted its holdings in shares of Thermo Fisher Scientific by 20.4% in the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company's stock worth $56,000 after purchasing an additional 19 shares during the last quarter. Renasant Bank grew its stake in Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company's stock worth $970,000 after buying an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. increased its position in Thermo Fisher Scientific by 5.4% in the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company's stock worth $212,000 after buying an additional 22 shares during the period. Legacy Wealth Managment LLC ID boosted its holdings in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the period. Finally, Chesapeake Wealth Management grew its position in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company's stock worth $1,868,000 after acquiring an additional 22 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO traded up $9.06 during trading on Wednesday, reaching $665.64. The stock had a trading volume of 860,901 shares, compared to its average volume of 2,246,559. The stock has a 50 day moving average of $622.56 and a two-hundred day moving average of $537.94. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $246.12 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 2.83 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $694.33.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 EPS. The company's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Insider Buying and Selling

In related news, CEO Marc Casper sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TMO. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, August 28th. Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Scotiabank started coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an "outperform" rating on the stock. Finally, Wells Fargo & Company lowered Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $633.13.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher’s growth case remains supported by innovation, acquisitions and broad demand across its end markets. The company’s latest quarter exceeded earnings and revenue expectations, while analysts project approximately $25.13 in fiscal 2026 EPS. Is This the Right Time to Add TMO Stock to Your Portfolio?
• Positive Sentiment: ClearBridge Investments cited strong third-quarter guidance and broadening demand as reasons for a favorable multi-year outlook, potentially helping explain the rebound following the recent selloff. Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
• Positive Sentiment: Thermo Fisher’s PPD clinical research business signed an agreement to support Quantum BioPharma’s Phase 2 multiple-sclerosis trial. The contract adds clinical-services revenue potential and reinforces the reach of its pharmaceutical-services platform. Quantum BioPharma Signs Contract with Thermo Fisher
• Positive Sentiment: New drug-development and manufacturing offerings showcased at CPHI Milan, including OSD Express, could improve customer adoption and support future growth in biopharma services. Thermo Fisher Showcases New Solutions
• Neutral Sentiment: The stock recently reached a new one-year high before retreating, suggesting strong momentum but also increased sensitivity to valuation and profit-taking.
• Negative Sentiment: Coverage continues to flag macroeconomic and foreign-currency risks. With TMO trading at a premium earnings multiple, any slowdown in demand or unfavorable currency movements could pressure the shares.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.